BR0011585A - Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna - Google Patents

Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna

Info

Publication number
BR0011585A
BR0011585A BR0011585-1A BR0011585A BR0011585A BR 0011585 A BR0011585 A BR 0011585A BR 0011585 A BR0011585 A BR 0011585A BR 0011585 A BR0011585 A BR 0011585A
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutically acceptable
activity
protein
treating
Prior art date
Application number
BR0011585-1A
Other languages
English (en)
Inventor
Shao Song Chu
Larry Andrew Alegria
Steven Lee Bender
Suzanne Pritchett Benedict
Allen J Borchardt
Robert Steve Kania
Mitchell David Nambu
Anna Maria Tempczyl Russel
Sepehr Sarshar
Dilip Bhumralkar
Zhengwei Peng
Yi Michelle Yang
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of BR0011585A publication Critical patent/BR0011585A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

"COMPOSTOS DE DIAMINOTIAZOL, PRó-DROGA FARMACEUTICAMENTE ACEITáVEL, METABóLITO FARMACEUTICAMENTE ATIVO OU SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE UMA CONDIçãO DE DOENçA DE MAMìFEROS MEDIADA POR ATIVIDADE DE CINASE DE PROTEìNA E MéTODO DE MODULAçãO DA ATIVIDADE DE UM RECEPTOR DE CINASE DE PROTEìNA". A presente invenção refere-se a compostos de diaminotiazol de Fórmula (1) que modulam e/ou inibem a atividade de certas cinases de proteínas. Estes compostos e composições farmacêuticas que os contêm são capazes de mediar a transdução do sinal da tirosina cinase no sentido de modular elou inibir a proliferação celular indesejada. A invenção também se refere ao uso profilático ou terapêutico desses compostos e composições e a métodos de tratamento de câncer, bem como outros estados de doenças associadas com angiogênese indesejada elou proliferação celular, tais como retinopatia diabética, glaucoma neovascular, artrite reumatóide e psoríase, através da administração de quantidades eficazes desses compostos.
BR0011585-1A 1999-06-04 2000-06-02 Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna BR0011585A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13781099P 1999-06-04 1999-06-04
PCT/US2000/015188 WO2000075120A1 (en) 1999-06-04 2000-06-02 Diaminothiazoles and their use for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
BR0011585A true BR0011585A (pt) 2002-03-19

Family

ID=22479135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011585-1A BR0011585A (pt) 1999-06-04 2000-06-02 Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna

Country Status (34)

Country Link
US (1) US6620828B2 (pt)
EP (1) EP1181283B1 (pt)
JP (1) JP2003501420A (pt)
KR (1) KR20020015333A (pt)
CN (1) CN1359380A (pt)
AP (1) AP2001002341A0 (pt)
AT (1) ATE288424T1 (pt)
AU (1) AU778071B2 (pt)
BG (1) BG106276A (pt)
BR (1) BR0011585A (pt)
CA (1) CA2371158A1 (pt)
CZ (1) CZ20014213A3 (pt)
DE (1) DE60017894T2 (pt)
EA (1) EA200101268A1 (pt)
EE (1) EE200100659A (pt)
ES (1) ES2234628T3 (pt)
HR (1) HRP20020008A2 (pt)
HU (1) HUP0202897A3 (pt)
IL (1) IL146094A0 (pt)
IS (1) IS6183A (pt)
MA (1) MA25530A1 (pt)
MX (1) MXPA01012483A (pt)
NO (1) NO20015045L (pt)
NZ (1) NZ514881A (pt)
OA (1) OA11959A (pt)
PE (1) PE20010211A1 (pt)
PL (1) PL352714A1 (pt)
SK (1) SK17302001A3 (pt)
SV (1) SV2002000096A (pt)
UA (1) UA71971C2 (pt)
UY (1) UY26190A1 (pt)
WO (1) WO2000075120A1 (pt)
YU (1) YU85601A (pt)
ZA (1) ZA200108291B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
ES2267873T3 (es) * 1997-10-27 2007-03-16 Agouron Pharmaceuticals, Inc. Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina.
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
IL159086A0 (en) * 2001-06-08 2004-05-12 Cytovia Inc 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
BRPI0313165B8 (pt) 2002-08-02 2021-05-25 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
AR041867A1 (es) * 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
HUE059464T2 (hu) 2003-04-11 2022-11-28 Ptc Therapeutics Inc 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1644323B1 (en) * 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
ZA200605624B (en) 2004-01-12 2007-11-28 Applied Research Systems Thiazole derivatives and use thereof
JPWO2005108370A1 (ja) * 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
AU2005271843A1 (en) * 2004-07-12 2006-02-16 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors
CA2608153C (en) 2005-05-24 2014-09-23 Laboratoires Serono S.A. Thiazole derivatives for use as p13k modulators
CA2607385C (en) * 2005-05-24 2014-12-16 Laboratoires Serono S.A. Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7691902B2 (en) * 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BRPI0706621A2 (pt) * 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
JP5369257B2 (ja) * 2006-02-15 2013-12-18 アッヴィ・インコーポレイテッド 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
WO2007095603A2 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US9289398B2 (en) 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
UA95298C2 (ru) 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
CN101910134B (zh) 2007-12-07 2014-03-19 沃泰克斯药物股份有限公司 环烷基甲酰氨基-吡啶苯甲酸类的生产方法
US8507534B2 (en) 2007-12-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20110098296A1 (en) * 2007-12-13 2011-04-28 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
CN103382201B (zh) 2008-02-28 2016-12-28 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
US8546433B2 (en) 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2011048936A1 (ja) * 2009-10-19 2011-04-28 大正製薬株式会社 アミノチアゾール誘導体
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
AU2014219855B2 (en) 2013-02-19 2017-09-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN112979574A (zh) 2014-03-06 2021-06-18 Ptc医疗公司 1,2,4-噁二唑苯甲酸的药物组合物和盐
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
JP2018531975A (ja) 2015-10-30 2018-11-01 ピーティーシー セラピューティクス，インコーポレーテッド てんかんの治療方法
CA3036245C (en) * 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en) 1981-05-27 1987-01-22 Labatt Brewing Co. Ltd. Malt sterilisation with hydrogen peroxide
US4994479A (en) 1985-04-03 1991-02-19 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives and anti-allergic use thereof
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0636123A1 (en) 1992-03-24 1995-02-01 MERCK SHARP & DOHME LTD. 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
ATE262902T1 (de) 1994-11-10 2004-04-15 Millennium Pharm Inc Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
CN1151147C (zh) 1995-02-02 2004-05-26 史密丝克莱恩比彻姆有限公司 作为5-ht受体拮抗剂的吲哚衍生物
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
ATE211740T1 (de) 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
WO1998009961A1 (en) 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
ES2267873T3 (es) * 1997-10-27 2007-03-16 Agouron Pharmaceuticals, Inc. Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina.
TR200001234T2 (tr) 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
HUP0100330A3 (en) 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) * 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.

Also Published As

Publication number Publication date
SV2002000096A (es) 2002-06-07
ES2234628T3 (es) 2005-07-01
NZ514881A (en) 2003-10-31
HUP0202897A3 (en) 2004-12-28
AU778071B2 (en) 2004-11-11
YU85601A (sh) 2004-09-03
AP2001002341A0 (en) 2001-12-31
KR20020015333A (ko) 2002-02-27
PE20010211A1 (es) 2001-03-16
DE60017894D1 (de) 2005-03-10
MXPA01012483A (es) 2002-07-30
EE200100659A (et) 2003-02-17
CN1359380A (zh) 2002-07-17
US20020025976A1 (en) 2002-02-28
SK17302001A3 (sk) 2004-01-08
EP1181283B1 (en) 2005-02-02
PL352714A1 (en) 2003-09-08
IS6183A (is) 2001-11-29
CA2371158A1 (en) 2000-12-14
CZ20014213A3 (cs) 2002-04-17
JP2003501420A (ja) 2003-01-14
EA200101268A1 (ru) 2002-06-27
NO20015045L (no) 2002-02-04
UA71971C2 (en) 2005-01-17
NO20015045D0 (no) 2001-10-17
UY26190A1 (es) 2000-12-29
DE60017894T2 (de) 2005-12-29
BG106276A (bg) 2002-10-31
OA11959A (en) 2006-04-17
HRP20020008A2 (en) 2004-02-29
US6620828B2 (en) 2003-09-16
WO2000075120A1 (en) 2000-12-14
IL146094A0 (en) 2002-07-25
HUP0202897A2 (hu) 2002-12-28
EP1181283A1 (en) 2002-02-27
MA25530A1 (fr) 2002-10-01
AU5725400A (en) 2000-12-28
ZA200108291B (en) 2002-12-24
ATE288424T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
BR0011585A (pt) Compostos de diaminotiazol,pró-droga farmaceuticamente aceitável,metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável,composição farmacêutica,método de tratamento de uma condição de doença de mamìferos mediada por atividade de cinase de proteìna e método de modulação da atividade de um receptor de cinase de proteìna
BR0012352A (pt) Compostos de indazol, pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo, ou sal farmaceuticamente aceitável, composições farmacêuticas, método para o tratamento de uma condição de doença de um mamìfero mediada pela atividade de proteìna cinase e método para modular a atividade de um receptor de proteìna cinase
BR0108025A (pt) Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase
BRPI0413051A (pt) compostos de indazol 3,5-dissubstituìdos, composições farmacêuticas e métodos para mediar ou inibir a proliferação celular
BR0317548A (pt) Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
BR0110302A (pt) Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
BR0107783A (pt) Compostos de indazol, seu sais farmaceuticamente aceitáveis, pró-drogas ou metabólitos farmaceuticamente ativos, composições farmacêuticas, método de tratamento de doenças ou disfunções mediadas pela inibição de um complexo de cinase, método de tratamento de doenças de mamìferos mediadas pela atividade de cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase, método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada, composição farmacêutica para o tratamento de estado doentio associado a proliferaçao celular descontrolada e método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada
ES2188595T3 (es) Derivados del acido 1-(2-oxo-acetil)-piperidin-2-carboxilico como sensibilizadores de celulas cancerosas resistentes a multiples farmacos.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
ATE427936T1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivitat
BR9713884A (pt) Benzamida heterociclicamente substituìda, usos da mesma e de cetobenzamidoaldeìdos desta, e, preparação medicamentosa.
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
BR0012610A (pt) Novo derivado de difenilpiperidina
PT1194415E (pt) Novos derivados da piperazinil-alquil-tiopirimidina composicoes farmaceuticas que os contem e um processo de preparacao da substancia activa
MXPA03001189A (es) Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
BR0113258A (pt) Compostos, pró-drogas, metabólitos ou sais, métodos de tratamento de condição doentia em mamìferos, mediada pela atividade de proteìna cinase e métodos de modulação ou inibição da atividade de um receptor de proteìna cinase
HUP0000108A2 (hu) Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására
Koley et al. Cardiovascular and respiratory changes following exposure to a synthetic toxin of Ptychodiscus brevis
TH75180B (th) สารประกอบอินดาโซลและองค์ประกอบทางเภสัชภัณฑ์ในการยับยั้งโปรตีนไคเนสและวิธีใช้ประโยชน์
BR9815690A (pt) Composto, processo para a preparação de qualquer um dos compostos, composição farmacêutica, e, uso do composto de 3-(nafter-1-il-óxi) - pirrolidina, 3-(5,6,7,8 - tetraidro-nafterc-1-il-óxi) - pirrolindina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.